[1]李万刚,崔 静,王建军,等.术前支气管动脉灌注化疗治疗Ⅲa（N2）期非小细胞肺癌[J].介入放射学杂志,2015,(02):160-165.
　LI Wan gang,CUI Jing,WANG Jian jun,et al.Preoperative bronchial artery infusion chemotherapy in the treatment of stage Ⅲa（N2） non small cell lung cancer[J].journal interventional radiology,2015,(02):160-165.
点击复制

术前支气管动脉灌注化疗治疗Ⅲa（N2）期非小细胞肺癌 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年02期
页码:
160-165
栏目:
临床研究
出版日期:
2015-02-25

文章信息/Info

Title:
Preoperative bronchial artery infusion chemotherapy in the treatment of stage Ⅲa（N2） non small cell lung cancer
作者:
李万刚;  崔 静;  王建军;  王继云;  张建伟;  刘本刚;  陈绍华
Author(s):
LI Wan gang;  CUI Jing;  WANG Jian jun;  WANG Ji yun;  ZHANG Jian wei;  LIU Ben gang;  CHEN Shao hua.
Department of Thoracic Surgery， Affiliated Petroleum Central Hospital of Tianjin Medical University， Central Hospital of China National Petroleum and Gas Corporation， Langfang， Hebei Province 065000， China
关键词:
【关键词】 支气管动脉灌注;  新铺助化疗;  非小细胞肺癌;  Ⅲa（N2）期;  手术
文献标志码:
A
摘要:
【摘要】 目的 探讨术前支气管动脉灌注（BAI）化疗在Ⅲa（N2）期非小细胞肺癌（NSCLC）治疗中的临床应用价值。方法 临床确诊的Ⅲa（N2）期非小细胞肺癌186例， 随机分为观察组和对照组，每组93例。观察组患者在接受2次BAI后手术，对照组确诊后直接手术，观察BAI疗效，比较两组患者的手术情况和术后生存率。结果 观察组的临床和组织学有效率分别为80.6%和83.9%，TNM分期下降50.53%，不良反应轻微；观察组根治性手术切除率为93.4%，显著高于对照组的72.0%，差异有统计学意义（P ＜ 0.05）；术中出血量和术后并发症两组间无差别；观察组与对照组1、3、5年生存率分别为97.8%、64.8%、36.3%和89.3%、50.5%、18.3%，两组间差异有显著统计学意义（P < 0.01）。结论 术前BAI可获得较好的临床和组织学疗效，并能提高Ⅲa（N2）期NSCLC的根治性手术切除率和术后生存率，值得临床推广应用。

参考文献/References:

［1］ 赵真真， 王忠敏， 茅爱武． 非小细胞肺癌的介入治疗现状［J］． 介入放射学杂志， 2014， 23： 272 276．
［2］ 李万刚， 崔进国． 支气管动脉灌注治疗肺癌的现状与展望［J］． 实用医学杂志， 2013， 29： 3460 3462．
［3］ Kolek V, Grygarkova I, Hajduch M, et al. Long term follow up of neoadjuvant adjuvant combination treatment of ⅢA stage non small cell lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in vitro chemoresistance test［J］. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2008, 152: 259 266.
［4］ Depierre A, Milleron B, Moro Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage Ⅰ (except T1N0), Ⅱ, and Ⅲa non small cell lung cancer［J］. J Clin Oncol, 2002, 20: 247 253.
［5］ Mellas N, Elmesbahi O, Masbah O, et al. Neoadjuvant chemotherapy in non small cell lung cancer: current state and future［J］. Bull Cancer, 2010, 97: 211 223.
［6］ Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant chemotherapy in non small cell lung cancer: an updated meta analysis of 13 randomized control trials［J］. J Thorac Oncol, 2010, 5: 510 516.
［7］ Bozcuk H, Abali H, Coskun S, et al. The correlates of benefit from neoadjuvant chemotherapy before surgery in non small cell lung cancer: a metaregression analysis［J］. World J Surg Oncol, 2012, 10: 161 169.
［8］ Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non small cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint［J］. Lancet Oncol, 2014, 15: e42 e50.
［9］ Vallières E. More questions about neoadjuvant chemotherapy in lung cancer［J］. Oncology (Williston Park), 2009, 23: 892 896.
［10］ Kim ES, Lee JJ, He G, et al. Tissue Platinum concentration and tumor response in non small cell lung cancer［J］. J Clin Oncol, 2012, 30: 3337 3344.
［11］ Schallier D, Neyns B, Fontaine C, et al. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC)［J］. Lung Cancer, 2007, 56: 247 254.
［12］ Betticher DC, Hsu Schmitz SF, T?觟tsch M, et al. Mediastinal lymph node clearance after docetaxel cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage ⅢA pN2 non small cell lung cancer: a multicenter phase Ⅱ trial［J］. J Clin Oncol, 2003, 21: 1752 1759.
［13］ Liao WY, Chen JH, Wu M, et al. Neoadjuvant chemotherapy with docetaxel cisplatin in patients with stage Ⅲ N2 non small cell lung cancer［J］. Clin Lung Cancer, 2013, 14: 418 424.
［14］ Jakobsen JN, Santoni Rugiu E, Sorensen JB. Longitudinal assessment of TUBB3 expression in non small cell lung cancer patients［J］. Cancer Chemother Pharmacol, 2014, 73: 43 51.
［15］ William WN, Pataer A, Kalhor N, et al. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non small cell lung cancer after neoadjuvant chemotherapy［J］. J Thorac Oncol, 2013, 8: 222 228.
［16］ Kappers I, Van Sandick JW, Burgers SA, et al. Surgery after induction chemotherapy in stage ⅢA N2 non small cell lung cancer: why pneumonectomy should be avoided［J］. Lung Cancer, 2010, 68: 222 227.
［17］ So T, Osaki T, Nakata S, et al. Carinal resection after induction bronchial arterial infusion for locally advanced non small cell lung cancer［J］. Jpn J Thorac Cardiovasc Surg, 2004, 52: 143 147.
［18］ Davidov MI, Polotzky BE, Marenich AF, et al. Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB ⅢA non small cell lung cancer［J］. Anticancer Drugs, 2011, 22: 569 575.
［19］ Ceylan KC, Kaya SO, Samancilar O, et al. The effects of neoadjuvant chemotherapy on pulmonary structures: a quantitative analysis［J］. Thorac Cardiovasc Surg, 2012, 60: 111 115.
［20］闫 东， 周纯武， 刘德忠， 等． 中心型非小细胞肺癌支气管动脉灌注疗效分析［J］． 中华肿瘤杂志， 2011， 33： 302 304．
［21］姚 珂， 向明章， 闵家新， 等． Ⅲ期非小细胞肺癌术前新辅助化疗的随机对照临床试验［J］． 中国肿瘤临床， 2004， 31： 611 613．
［22］ Koshy M, Fedewa SA, Malik R, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage Ⅲa(N2) non small cell lung cancer［J］. J Thorac Oncol, 2013, 8: 915 922.

备注/Memo

备注/Memo:
（收稿日期：２０１4-０7-2０）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2015-02-16